Sanofi pays $315M to settle claims it delayed Lemtrada to avoid investor payouts

lawsuit and book
Sanofi paid $315 million to resolve a 2015 lawsuit from Genzyme investors accusing the drugmaker of dragging its feet on Lemtrada. (Getty/eccolo74)

Sanofi has been battling claims that it dragged its feet on multiple sclerosis (MS) drug candidate Lemtrada, acquired in its Genzyme buyout, to avoid follow-up payments to investors. But now, the drugmaker is forking over $315 million to resolve those claims.

Former Genzyme shareholders sued Sanofi in 2015 alleging the company dragged its feet on Lemtrada to avoid payouts tied to its development and approval. Set up as contingent value rights as part of its Genzyme buy, the payouts weren't supposed to figure into Sanofi's decision-making as it advanced the drug.

But that's just what management did, investors claimed. "Sanofi took those potential milestone payments into account in evaluating Lemtrada’s profitability, embarked on a slow path to FDA approval and departed from its own drug-commercialization patterns and those of others in the industry," the suit claimed.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Sanofi didn't admit wrongdoing under the settlement but will pay more than $315 million to resolve the claims. Originally, the former Genzyme shareholders said the delays cost them $708 million. 

Sanofi picked up Genzyme in 2011 for $20 billion in one of biopharma’s most successful buyouts of the last decade. These days, Genzyme drugs are chipping in growth at the drugmaker as other areas of its business struggle. 

RELATED: Lawsuit claims Sanofi dragged its feet on Lemtrada OK to avoid rights payoff 

Lemtrada won approval in November 2014 and is operating in an increasingly crowded MS field. Sales for the drug peaked in 2017 at €474 million ($528 million). Last year, the drug generated €402 million ($448 million).

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.